I. Maremmani, M. Pacini, S. Canoniero, S. Lubrano, J.A. Deltito, J.M. Palumbo - Vol. 8, March 2002, Issue 1
Testo Bibliografia Summary Indice
Indicazioni psichiatriche degli antagonisti
degli oppiacei
Opioid-receptor antagonists in Psychiatry
1 Alger SA, Schwalberg MD, Bigaouette JM, Michalek AV, Howard LJ. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr 1991;53:865-71.
2 Armeanu MC, Berkhout GM, Schoemaker J. Pulsatile luteiniz-ing hormone secretion in hypothalamic amenorrhea, anorexia nervosa, and polycystic ovarian disease during naltrexone treatment. Fertility and Sterility 1992;57:762-70.
3 Bacopoulos NG, Spokes EG, Bird ED, et al. Antipsychothic drugs action in schizophrenic patients: effects on cortical dopamine metabolism after long-term treatment. Sci 1979;205:1405-7.
4 Baranowska B. Are disturbances in opioid and adrenergic sys-tems involved in the hormonal dysfunction of anorexia nervosa? Psychoneuroendocrinology 1990;15:371-9.
5 Barchas JD, Evans C, Elliott GR, Berger PA. Peptide neuroregulators: the opioid systems as a model. Yale J Biol Med 1985;58:579-96.
6 Basbaum AI, Fields HL. Endogenous pain control systems: Brainstem spinal patways and endorphin circuitry. Ann Rev Neurosci 1984;7:309-38.
7 Becker JA, Goldman MB, Alam MY, Luchins DJ. Effects of naltrexone on mannerism and water imbalance in polidypsic schizophrenics: a pilot study. Schizophr Res 1995;17:279-82.
8 Benjamin S, Seek A, Tresise L, Price E, Gagnon M. Case study: paradoxical responce to naltrexone treatment of self injurious behavior. J Am Acad Child Adolesc Psychiatry 1995;34:238-42.
9 Bissette G, Nemeroff CB, Mackay AV. Neuropeptides and schizophrenia. Progr Brain Res 1986;66:161-74.
10 Bloom SR, Polak JM. Clinical Aspects of gut hormones and neuropeptides. Br Med Bull 1982;38:233-8.
11 Bouvard MP, Leboyer M, Launay JM, Recasens C, Plumet MH, Waller-Perotte D, et al. Low doses Naltrexone effects on plasma chemistries and clinical symptoms in autism: a double blind placebo controlled study. Psychiatry Res 1995;58:191-201.
12 Brewerton TD, Ladyard RB, Laraia MT, Shook JE, Ballenger JC. CSF beta-endorphin and dynorphin in bulimia nervosa. Am J Psychiatry 1992;149/8:1086-90.
13 Calenco-Choukroun G, Dauge V, Gacel G, Roques BP. Lesion of dopamin mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by a mu-receptor opioid agonist. Eur J Pharmacology 1991;209:267-71.
14 Campbell M, Adams P, Small A. Naltrexone in infantile autism. Psychopharmacol Bull 1988;24:135-9.
15 Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993;32:1283-91.
16 Carrion VG. Naltrexone for the treatment of trichotillomania: a case report [Letter]. J Clin Psychopharmacol 1995;15:444-5.
17 Chappell PB, Leckman JF, Pauls D. Biochemical and genetic studies of Tourette’s syndrome. In: Deutsch SI, Weiz-man A, Weizman R, eds. Application of basic neuroscience to child psychiatry. New York: Plenum 1990.
18 Christenson GA, Raymond NC, Faris PL, McAllister RD, Crow SJ, Howard LA, et al. Pain thresholds are not elevated in trichotillomania. Biol Psychiatry 1994;36:347-9.
19 Ciraulo AM, Alpert N, Franko KJ. Naltrexone for the treatment of alcoholism. Am J Fam Physician 1997;56:803-6.
20 Coid J, Allolio B, Rees LH. Raised plasma metenkephalin in patients who habitually mutilate themselves. Lancet 1983;2:545-6.
21 Davidson TL, McKenzie BR, Tujo CJ, Bish CK. Development of tolerance to endogenous opiates activated by 24-h food de-privation. Appetite 1992;19:1-13.
22 De Marinis L, Folli G, D'Amico C, Mancini A, Sambo P, Tofani A, et al. Differential effects of feeding on the ultradian variation of the growth hormone (GH) response to GH-releasing hormone in normal subjects and pa-tients with obesity and anorexia nervosa. J Clin Endocrinol Metab 1988;66:598-604.
23 De Marinis L, Mancini A, Folli G, D'Amico C, Corsello SM, Sciuto R, et al. Naloxone inhibition of postprandial growth hormone releasing hormone-induced growth hormone release in obesity. Neuroendocrinol 1989;50:529-32.
24 De Marinis L, Mancini A, Zuppi P, Fiumara C, Fabrizi ML, Sammartano L, et al. Opioid dysregulation in anorexia nervosa: naloxone effects on preprandial and postprandial growth hormone response to growth hormone-re-leasing hormone. Metabolism 1994;43:140-3.
25 Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Godnell BA. Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese ond lean female binge eaters. Am J Clin Nutr 1995;61:1206-12.
26 Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 1992;51:371-9.
27 Garcia-Rubi E, Vazquez-Aleman D, Mendez JP, Salinas JL, Garza-Flores J, Ponce-de-Leon S, Pet al. The effects of opioid blockade and GnRH administration upon luteinizing hormone secretion in patients with anorexia nervosa during the stages of weight loss and weight recovery. Clin Endocrinol 1992;37:520-8.
28 Genazzani AD, Petraglia F, Gastaldi M, Volpogni C, Gamba O, Genazzani AR. Naltrexone treatment restores menstrual cycles in patients with weight loss related amenorrhea. Fertil Steril 1995;64:951-6.
29 Gitlin MJ, Gerner RH, Rosenblatt M. Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacol 1981;74:51-3.
30 Giugliano D. Opioid peptides and obesity. Eur J Med 1992;1:90-6.
31 Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with posttraumatic stress disorder. Israel J Psychiatry Rel Sci 1993;30:255-63.
32 Goldstein A, Lowney LI, Pal BK. Stereospecific and nonspe-cific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc Nat Acad Sci USA 1971;68:1742-7.
33 Gorelick DA. Pharmacological treatment. Recent Develop Alcohol 1993;11:413-27.
34 Hagan MM, Moss DE. Effect of naloxone and antidepressants on hyperphagia produced by peptide YY. Pharmacol Biochem Behav 1993;45:941-4.
35 Hartmann PM. Naltrexone in alcohol dependence. Am J Fam Phys 1997;55:1877-84.
36 Herman BH. A possible role of proopiomelanocortin peptides in self injurious behavior. Progr Neuro-psychopharmacol Biol Psychiatry 1990;14:S109-39.
37 Herman BH, Hammock MK, Arthur-Smith A, Egan J, Chatoor I, Werner A, et al. Naltrexone decreases self injurious behavior. Ann Neurol 1987;22:550-2.
38 Hockings GI, Grice JE, Ward WK, Walters MM, Jensen GR, Jackson RV. Hypersensitivity of the hypothalamic-pituitary-adrenal axis to naloxone in postraumatic stress disorder. Biol Psychiatry 1993;33:585-93.
39 Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of tworelated pentapeptides from the brain with potent opiate ago-nistactivity. Nature 1975;258:577-80.
40 Igoin-Apfelbaum L, Apfelbaum M. Naltrexone and bulimic symptoms. Lancet 1987;2:1087-8.
41 Insel TR, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry 1983;140:1219-20.
42 Jasinski DR, Martin WR, Sapira JD. Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone. Clin Pharmacol Ther 1968;9:215-22.
43 Jonas JM, Gold MS. Naltrexone treatment of bulimia: clinical and theoretical findings linking eating disorders and substance abuse. Advances Alcohol Substance Abuse 1987;7:29-37.
44 Jonas JM, Gold MS. The use of opiate antagonists in treating bulimia: a study of low dose vs high dose naltrexone. Psychiatry Res 1988;24/2:195-9.
45 Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 1996;40:154-6.
46 Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: a double blind placebo controlled cross-over study. J Am Acad Child Adol Psychiatry 1995;34:223-31.
47 Kosten TA, Kosten TR. Pharmacological blocking agents for treating substance abuse. J Nerv Mental Dis 1991;179:583-92.
48 Krotkiewski M, Fagerberg B, Bjorntorp P, Terenius L. Endorphins in genetic human obesity. Intern J Obesity 1983;7:597-8.
49 Kurlan R, Majumdar L, Deeley C, Mudholkar GS, Plumb S, Como PGl. A controlled trial of propoxyphene and naltrexone in patients with Tourette’s syndrome. Ann Neurol 1991;30:19-23.
50 Kurland AA, McCabe OL, Hanlon TE, Sullivan D. The tratment of perceptual disturbances in schizophrenia with naloxone hydrochloride. Am J Psychiatry 1977;134:1408-10.
51 Kyriakides M, Silverstone T, Jeffcoate W, Laurance Bl. Effect of nal-oxone on hyperphagia in Prader-Willi syndrome [letter]. Lancet 1980;1:876-7.
52 Leboyer M, Bouvard M, Lensing P. The opioid excess hypothesis of autism: a double-blind study of naltrexone. Brain Dysfunction 1990;3:285-99.
53 Leboyer M, Bouvard MP, Launay JM, Recasens C, Plumet MH, Waller-Perotte D, et al. Une hypothèse opiacée dans l’autisme infantile? Encephale 1993;19:95-102.
54 Leckman JF, Riddle MA, Berrettini WH, Anderson GM, Hardin M, Chappell P, et al. Elevated CSF dynorphin A [1-8] in Tourette’s syndrome. Life Sci 1988;43:2015-23.
55 Lienemann J, Walker F. Naltrexone for treatment of self injury [Letter]. Am J Psychiatry 1989;146:1639-40.
56 Lindstrom LH, Widerlov E, Gunne LM, Wahlstrom A, Terenius L. Endorphins in human cerebrospinal fluid: clinical correlations to some psychothic states. Acta Psychiatr Scand 1978;57:153-64.
57 Litten RZ, Allen JP. Reducing the desire to drink: Pharmacology and neurobiology. In: Galanter M, ed. Recent Developments in Alcoholism, vol 11: Ten Years of Progress. New York, NY: Plenum 1993:325-44.
58 Luby ED, Marrazzi MA, Kinzie J. Treatment of chronic anorexia nervosa with opiate blockade. J Clin Psychopharmacol 1987;7:52-3.
59 Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNSopioid receptors. Trends Neurosci 1988;11:308-31.
60 Marchesi GF, Santone G, Cotani P, Giordano A, Chelli F. Neltrexone in chronic negative schizophrenia. Clin Neuropharmacol 1992;15(Suppl 1,Pt.A):56A-57A.
61 Marchesi GF, Santone G, Cotani P, Giordano A, Chelli F. The therapeutic role of naltrexone in negative schizophrenia. Biol Psychiatry 1995;19:1239-49.
62 Maremmani I, Daini L, Zolesi O, Castrogiovanni P. Use of Fluoxetine in heroin addiction. Br J Psychiatry 1992;160:570-1.
63 Maremmani I, Marini G, Castrogiovanni P, Deltito J. The effectiveness of the combination Fluoxetine-Naltrexone in Bulimia Nervosa. Europ Psychiatry 1996;11:322-4.
64 Maremmani I, Marini G, Fornai F. Naltrexone induced Panic Attacks. Am J Psychiatry 1998;155:447.
65 Maremmani I, Zolesi O, Daini L, Castrogiovanni P, Tagliamonte A. Fluoxetine improves outcome in Addicted Patients Treated With Opioid Antagonists. Am J Add 1995;4:267-71.
66 Marrazzi MA, Bacon JP, Kinzie J, Luby ED. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Intern Clin Psychopharmacol 1995;10:163-72.
67 Marrazzi MA, Mullings-Britton J, Stack L, Powers RJ, Lawhorn J, Graham V, et al. Atypical en-dogenous opioid systems in mice in relation to an auto-addic-tion opioid model of anorexia nervosa. Life Sci 1990;47:1427-35.
68 Marrazzi MA, Wroblewski JM, Kinzie J, Luby ED. High-dose naltrexone and liver function safety. Am J Add 1997;6:21-9.
69 Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects ofmorphine- and nalorphine- like drugs in the nondependentand morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517-32.
70 McConville BJ, Norman AB, Fogelson MH, Erenberg G. Sequential use of opioid antagonists and agonists in Tourette’s syndrome [letter]. Lancet 1994;343:601.
71 Mielke DH, Gallant DM. An oral opiate antagonist in chronic schizophrenia: a pilot study. Am J Psychiatry 1977;134:1430-1.
72 Mitchell JE, Christenson GJJ, Huber M, Thomas B, Pomeroy C, Morley J. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. J Clin Psychopharmacol 1989;9:94-7.
73 Moore R, Mills IH, Forster A. Naloxone in the treatment of anorexia nervosa: effect on weight gain and lipolysis. J Royal Soc Med 1981;74:129-31.
74 Morley JE. Neuropeptide regulation of appetite and weight. Endocrine Rev 1987;8:256-87.
75 Myers RD. New drugs for the treatment of experimental alcoholism. Alcohol 1994;11:439-51.
76 Neumeister A, Winkler A, Wober-Bingol C. Addition of naltrexone to fluoxetine in the treatment of binge eating disorder. Am J Psychiatry 1999;156:797.
77 Nieuwenhuys R. Chemoarchitecture of the brain. New York: Springer-Verlag 1985.
78 O’Brien CP, Volpicelli LA, Volpicelli J. Naltrexone in the treatment of alcoholism: a clinical revue. Alcohol 1996;13:35-9.
79 O’Malley SS. Opioid antagonist in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol and Alcoholism Suppl 1996;1:77-81.
80 Olson G, Olson RD, Kastin AJ. Endogenous opiates: 1992. Peptides 1993;14:1339-78.
81 Panksepp J. A neurochemical theory of autism. Trends Neurosci 1979;2:174-7.
82 Panksepp J, Herman B, Vilberg T. Endogeneous opioids and social behavior. Neurosci Biobehav Rev 1980;4:473-87.
83 Panksepp J, Lensing P. Naltrexone treatment of autism: a synopsis of an open-trial with four children. J Autism Dev Dis 1991;21:243-9.
84 Panza G, Monzani E, Sacerdote P, Penati G, Panerai AE. Beta-endorphin, vaso-active intestinal peptide and cholecystokinin in peripheral blood mononuclear cells from healthy subjects and from drug-free and haloperidol-treated schizophrenic patients. Acta Psychiatrica Scandinavica 1992;85:207-10.
85 Pasternak GW, Goodman R, Snyder SH. An endogenous mor-phine-like factor in mammalian brain. Life Sci 1975;16:1765-9.
86 Pickar D, Bunney WE Jr, Douillet P, Sethi BB, Sharma M, Vartanian ME, et al. Repeated naloxone administration in schizophrenia: a phase II WHO study. Biol Psychiatry 1989;25:440-8.
87 Pickar D, Naber D, Post RM, van Kammen DP, Kaye W, Rubinow DR, et al. Endorphins in the cerebrospinal fluid of psychiatric patients. Ann NY Acad Sci 1982;398:399-412.
88 Pickar D, Vartanian F, Bunney WE Jr, Maier HP, Gastpar MT, Prakash R, et al. Short-term naloxone administration in schizophrenic and manic patients. A WHO Collaborative Study. Arch Gen Psychiatry 1982;39:313-9.
89 Rapaport MH, Wolkowitz O, Kelsoe JR, Konicki PE, Pickar D. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients. Neuropsychopharmacol 1993;9:111-5.
90 Richardson JS, Zalesky WA. Naloxone and self mutilation. Biol Psychiatry 1983;18:99-101.
91 Rittmansberger H, Silverbauer C, Lehner R, Ruskak M. Alcohol consumption during methadone maintenance treatment. Eur Add Res 2000;6:2-7.
92 Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self injurious behavior. J Clin Psychiatry 1996;57:233-7.
93 Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette’s syndrome. Intern J Neurosci 1987;35:93-4.
94 Simon EJ, Hiller JM, Edelman J. Stereospecific binding of the potent narcotic analgesic (3H)etorphine to rat brain homogenate. Proceed Nat Acad Sci USA 1973;70:1947-9.
95 Sonne S, Rubey R, Brady K, Malcolm R, Morris T. Naltrexone treatment of self injurious thoughts and behaviours. J Nerv Mental Dis 1996;184:192-5.
96 Terenius L. Stereospecfic interaction between narcotic analgecics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacol 1973;32:317-20.
97 Terenius L, Wahlström A. Search for an endogenous ligand forthe opiate receptor. Acta Physiol Scand 1975;94:74-81.
98 Toru N, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of schizophrenic patients. Acta Psychiatr Scand 1988;78:121-37.
99 Trenchard E, Silverstone T. Naloxone reduces the food intake of normal human volunteers. Appetite 1983;4.
100 van der Kolk BA, Greenberg MS, Orr SP, Pitman RK. Endogenous opioids, stress induced analgesia, and postraumatic stress disorder. Psychopharmacol Bull 1989;25:417-24.
101 Verebey, K. Opioids in mental illness: theories, clinical observations and treatment possibilities. New York, N.Y.: New York Acad Sci 1982.
102 Verhoeven WM, van Praag HM, van Ree JM. Repeated naloxone administration in schizophrenia. Psychiatry Res 1984;12:297-312.
103 Volavka J, Anderson B, Koz G. Naloxone and naltrexone in mentall illness and tardive diskynesia. Ann New York Acad Sci 1982;398:97-102.
104 Weizman R, Gil-Ad I, Dick J, Tyano S, Szekely GA, Laron Z. Low plasma immunoreactive beta endorphin levels in autism. J Am Acad Child Adol Psychiatry 1988;27:430-3.
105 Wiegant VM, Verhoef CJ, Burbach JP, De Kloet ER, Wiegant VM, Sweep CG, et al. Increased concentration of alpha- and gamma-endorphin in post mortem hypoyhalamic tissue of schizophrenic patients. Life Sci 1988;42:153-64.
106 Wikler A. Opiate addiction. Spriengfield, IL: Charles C. Thomas 1953.
107 Wikler A. Requirements for extinction of relapse-facilitating variabbles an for rehabilitation in a narcotic-antagonist treatment program. In: Broude MC, Harris LS, May EL, Smith JP, Villareal JE, eds. Narcotic Antagonists. Advances in biochemical psychopharmachology. New York: Raven press 1974:399-41.
108 Wikler A. The theoretical basis of narcotic addiction treatment with narcotic antagonist. Julius D, Renault P, eds. Narcotic Antagonists: Naltrexone. Rockville, Md: The Institute: NIDA Res Monograph 9. 1976:119-22.
109 Wikler A. Opioid Dependence. New York, NY: Plenum 1980.
110 Wikler A. A theory of opioid dependence. In: Lettieri DJ, Sayers M, Pearson HW, eds. Theories on drug abuse. Selected contemporary perspectives. Nida Research Monograph 30. Rockville, Md: N.I.D.A. 1980:174-8.
111 Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, van England H. Failure of naltrexone hydrochloride to reduce self injurious and autistic behavior in mentally retarded adults. Archives of General Psychiatry 1995;52:766-773.
112 Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, Thijssen JH, Van Engeland H. Plasma beta endorphins concentration in people with learning disability and self injurious and/or autistic behaviour. Br J Psychiatry 1996;168:105-9.
113 Zaks A, Jones T, Fink M, Freedman AM. Naloxone treatment of opiate dependence. JAMA 1971;215:2108-10.
114 Zlotkin SH, Fettes IM, Stallings VA. The effects of naltrexone, an oral beta-endorphin antagonist, in children with the Pra-der-Willi syndrome. J Clin Endocrinol Metab 1986;63:1229-32.